Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX)‘s stock had its “sell” rating reiterated by investment analysts at Piper Jaffray Companies in a research note issued to investors on Sunday. They presently have a $14.00 target price on the specialty pharmaceutical company’s stock. Piper Jaffray Companies’ price objective would suggest a potential upside of 0.57% from the company’s current price.

A number of other equities research analysts also recently weighed in on VRX. Vetr raised Valeant Pharmaceuticals International from a “strong sell” rating to a “sell” rating and set a $12.46 target price on the stock in a research report on Monday. HC Wainwright set a $17.00 target price on Valeant Pharmaceuticals International and gave the stock a “hold” rating in a research report on Wednesday, August 9th. Canaccord Genuity set a $14.00 target price on Valeant Pharmaceuticals International and gave the stock a “hold” rating in a research report on Thursday, August 10th. Stifel Nicolaus reissued a “buy” rating and set a $35.00 target price on shares of Valeant Pharmaceuticals International in a research report on Thursday, August 10th. Finally, Wells Fargo & Company reissued an “underperform” rating and set a $9.00 target price on shares of Valeant Pharmaceuticals International in a research report on Thursday, August 10th. Five analysts have rated the stock with a sell rating, fourteen have given a hold rating and four have given a buy rating to the stock. Valeant Pharmaceuticals International currently has a consensus rating of “Hold” and an average target price of $17.62.

Valeant Pharmaceuticals International (VRX) opened at 13.92 on Friday. Valeant Pharmaceuticals International has a 12-month low of $8.31 and a 12-month high of $27.84. The company’s market cap is $4.85 billion. The firm’s 50-day moving average price is $14.39 and its 200-day moving average price is $13.19.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last posted its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 EPS for the quarter, topping analysts’ consensus estimates of $0.97 by $0.08. The business had revenue of $2.23 billion for the quarter, compared to analyst estimates of $2.23 billion. Valeant Pharmaceuticals International had a positive return on equity of 59.89% and a negative net margin of 12.40%. The firm’s revenue for the quarter was down 7.7% on a year-over-year basis. During the same period in the previous year, the company posted ($0.88) earnings per share. Analysts expect that Valeant Pharmaceuticals International will post $3.89 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Valeant Pharmaceuticals International, Inc. (VRX) Given “Sell” Rating at Piper Jaffray Companies” was reported by Daily Political and is the sole property of of Daily Political. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The correct version of this story can be read at https://www.dailypolitical.com/2017/09/17/valeant-pharmaceuticals-international-inc-vrx-given-sell-rating-at-piper-jaffray-companies.html.

In related news, Director Schutter Richard U. De acquired 10,000 shares of the company’s stock in a transaction that occurred on Monday, August 21st. The stock was purchased at an average price of $14.33 per share, for a total transaction of $143,300.00. Following the transaction, the director now directly owns 77,479 shares of the company’s stock, valued at approximately $1,110,274.07. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 5.87% of the company’s stock.

Hedge funds have recently bought and sold shares of the stock. Gruss & Co. Inc. bought a new position in Valeant Pharmaceuticals International in the 1st quarter worth approximately $104,000. Harbor Advisors LLC bought a new position in Valeant Pharmaceuticals International in the 1st quarter worth approximately $110,000. NEXT Financial Group Inc raised its position in shares of Valeant Pharmaceuticals International by 6.2% during the 2nd quarter. NEXT Financial Group Inc now owns 10,303 shares of the specialty pharmaceutical company’s stock valued at $178,000 after acquiring an additional 600 shares during the last quarter. Financial Architects Inc raised its position in shares of Valeant Pharmaceuticals International by 10.5% during the 2nd quarter. Financial Architects Inc now owns 10,550 shares of the specialty pharmaceutical company’s stock valued at $183,000 after acquiring an additional 1,000 shares during the last quarter. Finally, WMS Partners LLC bought a new stake in shares of Valeant Pharmaceuticals International during the 1st quarter valued at $116,000. Hedge funds and other institutional investors own 50.49% of the company’s stock.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.